Deciphex, founded in 2017 and headquartered on Dublin City University’s Alpha campus, offers two core products: Diagnexia, which links a global pool of subspecialty pathologists for rapid case turnaround, and Patholytix, which streamlines preclinical safety assessments in drug development. These platforms collectively manage more than 97,000 cases per year through a network of 250+ pathologists. The company employs roughly 220 people across sites in Dublin, Exeter, Oxford, Chicago and Toronto, and it already serves customers in the EU, UK, US, Canada and Japan. Deciphex’s technology focuses on replacing manual, repetitive histopathology processes with AI-driven workflows to deliver faster, more reliable diagnoses. The firm aims to become the leading histopathology reporting provider in the UK by 2027 while simultaneously building a significant U.S. presence. Recognition of its execution includes being named the Irish Medtech Association’s Medtech Company of the Year in 2023. Recent financings—€31 m Series C equity followed by €15 m in venture debt—provide resources for continued international expansion.

Total raised

$72M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Oct 2025